I'm just thinking results from the KRAS study they have in Rida as well as the prostate trial; possible results in later 2011 (similar to the unblinding which occurred in the Endometrial study).
Either way - I think all of what is being posted amounts to one thing: most of the risk is out of this stock now that SUCCEED is behind us (assuming some disaster doesn't occur in 534)
This is probably the one of the best oncology "idea" stocks around right now - with ponatinib. And, I still don't think its on the radar screen of a lot of mo mo investors.
News 
Market Data 
Discover 
